Afinum acquires majority of biotech company evitria, a leading provider of custom antibodies
evitria (www.evitria.com) of Schlieren (Switzerland) is one of the leading providers of custom antibodies for research purposes. The company was founded 2010 by Dr. Markus Hildinger.
Customers of evitria are typically renowned pharmaceutical and biotech companies as well as research institutions. Many of them are leading producers of blockbuster antibody drugs. The customers have a constant demand for specific antibodies tailored to their respective research purposes; they use evitria as a highly specialized and trustworthy outsourcing partner.
Through the deployment of a unique, highly standardized and automized production process, evitria is able to minimize throughput times and guarantees high concentration
and quality levels. The company has been conducting more than 30,000 transfections and has been producing more than 5,000 different antibodies.
Together with management and SHS, AFINUM plans to further push internationalization in the years to come, supported by an active customer acquisition program.
The investment in evitria represents the fifth platform investment of Afinum Achte Beteiligungsgesellschaft mbH & Co. KG.